• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Industry Briefs

Industry Briefs

January 22, 2018

Informed Consent Common Rule Revisions Delayed for Six Months, But Certain Changes Can Continue

The federal government pushed back its revisions to the Common Rule for an additional six months — making the announcement less than 36 hours before the changes were set to take effect Jan. 19 — and warned the public to expect additional delays down the line.

The Common Rule encompasses the federal regulations and policies that govern the protection of human research subjects, including informed consent procedures and institutional review boards, and spans at least 16 departments and agencies.

The new implementation date is currently set for July 19 — but HHS, the Consumer Product Safety Commission and the Environmental Protection Agency, as well as the departments of Veterans Affairs, Defense, Commerce and others, are all currently developing a new proposed rule to further delay the changes, which were first announced in January 2017.

Until then, sponsors must continue to comply with current regulations, until the so-called “2018 regulations” finally go into effect — causing disruptions with companies participating in Common Rule-agency funded research that planned to comply with the Jan. 19 implementation date.

However, companies can begin implementing certain new elements of informed consent before July 19 — because they are not prohibited by current law, according to the HHS Office of Human Research Protections. 

“Institutions may begin implementing provisions of the revised Common Rule that do not conflict with the pre-2018 Common Rule,” OHRP said in announcing the delay this week.

However, certain new provisions cannot be implemented early, such as the elimination of the need for continuing review in certain circumstances.

“Because the pre-2018 regulations require continuing review at least annually for all ongoing non-exempt human subjects research, halting continuing review for such research before that date would be considered non-compliance,” OHRP said.

Oracle Survey Polls Challenges for Implementing Digital Trial Management Systems

A new survey described the main challenges for clinical trial professionals using current randomization and trial supply management and interactive response technology systems — with over 70 percent of respondents pointing to a lack of flexibility, integration with other platforms and the time burden it takes to deploy new trials as their major frustrations. The online survey, conducted by Oracle Health Sciences and Informa Engage, found that 92 percent reported having to make changes to their RTSM/IRT systems due to study changes, and at least twice per study on average. The most anticipated change in the next five years is the integration of IRT into the platform, followed by accelerated trial builds and self-service solutions, according to the study, which polled 254 professionals in clinical operations, trial management and related areas

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing